Zura Bio Limited (ZURA)

Market Cap	628.08M +582.2%
Revenue (ttm)	n/a
Net Income	-62.52M
EPS	-0.67
Shares Out	94.88M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	406,177
Open	6.75
Previous Close	6.77
Day's Range	6.40 - 6.82
52-Week Range	0.97 - 7.19
Beta	0.21
Analysts	Strong Buy
Price Target	11.78 (+77.95%)
Earnings Date	Mar 24, 2026

About ZURA

Zura Bio Limited, a clinical-stage biotechnology company, develops medicines for immune and inflammatory disorders in the United States. The company develops Tibulizumab, an immunoglobulin G-single-chain variable fragment bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes interleukin (IL)-17A and B-cell activating factor, which is in Phase 2 clinical trial development. It is also developing Torudokimab (ZB-880), a monoclonal antibody that neutralizes IL-33 to prevent ST2-dependent and ST2-i...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2022
• Employees: 30
• Stock Exchange: NASDAQ
• Ticker Symbol: ZURA
• Website: https://zurabio.com

Analyst Summary

According to 9 analysts, the average rating for ZURA stock is "Strong Buy." The 12-month stock price target is $11.78, which is an increase of 77.95% from the latest price.

Price Target

$11.78

(77.95% upside)

Analyst Consensus: Strong Buy